




Figure 1. The levonorgestrel intrauterine 
device (LIUD) 
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 Endometrial cancer is the most common 
gynecologic cancer in the United States with 
over 66,000 women diagnosed in 2020. 
 The standard of care for early stage
endometrial cancer is complete surgical 
resection. 
 The average age for women diagnosed with 
endometrial cancer is 60 years, however,  
25% of patients are premenopausal and 
many are still of childbearing age. 
 Surgical resection may not the ideal course 
of action for young women who want children 
in the future or women who are unable to 
have the surgery performed due to medical 
co-morbidities. 
 The levonorgestrel intrauterine device (LIUD) 
releases a consistent dose of progesterone 
into the uterine cavity for five years. 
 LIUD has been used in lieu of a surgical 
resection for atypical hyperplasia (AH) and 
grade 1 endometrioid endometrial carcinoma 
(EEC) with response rates for 85% and 65%, 
respectively, but resistance to progesterone 
can be observed.
.
 This trial will study the levonorgestrel 
intrauterine device (LIUD) alone or in 
combination with an mTORC1 inhibitor 
(everolimus) to overcome progesterone 
resistance in AH or stage Ia grade 1 EEC.
 In addition, we will assess clinical, 
pathologic, and molecular factors 
associated with progesterone resistance. 
METHODS
 Tissue collection is feasible in a multicenter 
study. 
 Analysis of the data collected on study is 
ongoing. 
 There have been 57 patients have been 
treated with the LIUD during the first stage 
of this ongoing study. 
 18 patients continued into stage 2 of the 
study with 9 being treated with LIUD alone 
and 9 with the combination of LIUD and 
everolimus. 
 To date, tissue has been collected from 16 
patients at all three time points.
 This multicenter study is a two-stage, randomized phase II trial of the LIUD alone or in 
combination with everolimus for the treatment of patients with AH or stage Ia, grade 1 
EEC. 
 Patients will have adequate organ and bone marrow function. 
 Well controlled diabetes is permitted on study. 
 In the first stage , patients without prior treatment with have LIUD placed at the time of 
confirmatory dilation and curettage. 
 Biopsy obtained after 3 months of treatment. 
 Those patients that have residual disease are deemed progesterone resistant and 
proceed to the second stage. 
 Patients with LIUD in place for at least 3 months prior to study that have residual disease 
are deemed progesterone resistant will progress immediately to second stage. 
 In stage 2, if progesterone resistance is identified, patients are randomized to either 
the LIUD alone or in combination with everolimus. 
 Approximately 270 women with AH or grade 1 EEC will participate in the first stage of 
the study. 
 We will randomize 80 patients in the second stage to achieve adequate power to 
detect difference in response. 
 For translational objectives, tissue is obtained at baseline, 3 months, and 6 months. 
 Molecular factors, including baseline and change in gene/protein expression in 
relevant pathways such as PI3K/AKT, estrogen-regulation, and Wnt signaling, will be 
associated with response and resistance to therapy.  
Primary: 
 Estimate the efficacy of the LIUD alone to 
treat complex atypical hyperplasia or stage Ia
grade 1 endometrioid endometrial carcinoma 
with response rate.
 Estimate the efficacy of the LIUD in 
combination with everolimus to treat LIUD-
refractory complex atypical hyperplasia or 
stage Ia grade 1 endometrioid endometrial 
carcinoma with response rate.
Secondary:
 Document the toxicity profile of the LIUD 
alone or in combination with everolimus
using the NIH- NCI Common Terminology 
Criteria for Adverse Events v4.0.
 Estimate overall survival (OS) and event-free 
survival (EFS) of patients with complex 
atypical hyperplasia or stage Ia grade 1 
endometrioid endometrial cancer treated with 
the LIUD alone or in combination with 
everolimus.
 Estimate the response duration associated 
with the LIUD alone or in combination with 
everolimus in patients with complex atypical 
hyperplasia or stage Ia grade 1 endometrioid 
endometrial cancer.
Exploratory:
 Determine if response to therapy can be 
predicted based on the molecular profile of 
the tumor, including estrogen-induced genes 
and relevant pathway members, or by 




Table 1: Current patient enrollment on LEVER trial 
